MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
Status:
Completed
Trial end date:
2020-12-03
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam)
compared with that of meropenem in pediatric participants with cUTI, including
pyelonephritis.